JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Scope & Guideline

Transforming Knowledge into Therapeutic Solutions

Introduction

Welcome to the JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0022-3565
PublisherAMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1945 to 2024
AbbreviationJ PHARMACOL EXP THER / J. Pharmacol. Exp. Ther.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995

Aims and Scopes

The Journal of Pharmacology and Experimental Therapeutics (JPET) aims to advance the understanding of pharmacological principles and experimental therapeutics through comprehensive research articles. The journal focuses on the intersection of pharmacology and therapeutics, providing a platform for innovative studies that bridge basic science and clinical applications.
  1. Pharmacological Mechanisms:
    Research exploring the mechanisms of drug action at various biological targets, including receptor interactions, signaling pathways, and metabolic processes.
  2. Therapeutic Applications:
    Studies investigating the efficacy and safety of therapeutic agents in various disease models, emphasizing clinical relevance and translational potential.
  3. Drug Development and Delivery:
    Research focused on novel drug formulations, delivery systems, and technologies aimed at improving the pharmacokinetic and pharmacodynamic profiles of therapeutics.
  4. Neuroscience and Behavior:
    Papers examining the effects of pharmacological agents on neurological function and behavior, particularly in models of pain, addiction, and neurodegenerative diseases.
  5. Toxicology and Safety Assessment:
    Studies evaluating the safety profiles of drugs and their metabolites, including toxicity mechanisms and the impact of environmental factors.
  6. Pharmacogenomics and Personalized Medicine:
    Research addressing the genetic and molecular basis of individual responses to drugs, aiming to optimize therapeutic strategies through personalized approaches.
The Journal of Pharmacology and Experimental Therapeutics is currently witnessing several emerging themes that reflect the evolving landscape of pharmacological research. These trends highlight the journal's responsiveness to contemporary challenges in therapeutics and drug development.
  1. Nanomedicine and Drug Delivery Systems:
    There is a growing trend towards the exploration of nanotechnology in drug delivery, with research focusing on enhancing the efficacy and targeting of therapeutics using nanoparticle systems.
  2. Cannabis and Cannabinoid Research:
    An increased focus on the therapeutic potential of cannabinoids in various medical conditions, including pain management and neuroprotection, is evident in recent publications.
  3. Gene Therapy and Biologics:
    Research into gene therapy, including the use of RNA-based therapeutics and monoclonal antibodies, has gained traction, reflecting advancements in biopharmaceuticals.
  4. Chronic Pain and Opioid Alternatives:
    There is a significant emphasis on identifying non-opioid alternatives for pain management, addressing the opioid crisis through innovative pharmacological strategies.
  5. Translational Pharmacology and Precision Medicine:
    Emerging studies are increasingly focusing on translational pharmacology, emphasizing the integration of pharmacogenomics to tailor therapies to individual patient profiles.
  6. Microbiome and Pharmacology:
    Research exploring the interactions between the microbiome and pharmacological agents is becoming more prominent, highlighting its implications for drug metabolism and therapeutic outcomes.

Declining or Waning

While the Journal of Pharmacology and Experimental Therapeutics continues to thrive in many areas, certain themes have been observed to decline in prominence over recent years. This could reflect shifting research priorities or emerging trends that overshadow previous areas of focus.
  1. Traditional Medicinal Approaches:
    Research focusing on classical herbal or traditional medicinal practices appears to have waned, as more emphasis is placed on molecular and mechanistic studies.
  2. Single-Agent Pharmacotherapy:
    The interest in studies solely focused on single-agent pharmacotherapy is declining in favor of combination therapies and polypharmacy approaches that consider multi-target strategies.
  3. Basic Pharmacokinetic Studies:
    There is a noticeable reduction in the publication of basic pharmacokinetic studies, with an increasing preference for more complex modeling approaches and real-world evidence.
  4. Animal Models of Drug Interaction:
    Research centered exclusively on animal models for drug-drug interactions has decreased, likely due to the emerging focus on human-based studies and advanced computational models.
  5. In vitro Studies without Clinical Relevance:
    Papers reporting in vitro findings without clear translational implications or clinical relevance are less frequently accepted, reflecting a shift towards applied research.

Similar Journals

INDIAN JOURNAL OF PHARMACOLOGY

Advancing pharmacological knowledge for a healthier tomorrow.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0253-7613Frequency: 6 issues/year

INDIAN JOURNAL OF PHARMACOLOGY, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the field of pharmacology and its related disciplines. With a rich history since its inception in 1978, this journal aims to disseminate high-quality research findings, reviews, and clinical studies that contribute to the global understanding of drug action and therapeutic practices. As a valuable resource for researchers, professionals, and students alike, it operates within the Q3 quartile of the Pharmacology category, positioning itself as an influential contributor in the realm of medical pharmacology. The journal is committed to publishing rigorous scientific inquiry, fostering innovation, and bridging gaps between laboratory research and clinical application. Readers can access its wide-ranging articles to stay informed about the latest advancements in the field, reflecting its crucial role in shaping future pharmacological research and practice.

DARU-Journal of Pharmaceutical Sciences

Fostering open access to transformative pharmaceutical research.
Publisher: SPRINGER INT PUBL AGISSN: Frequency: 2 issues/year

DARU-Journal of Pharmaceutical Sciences is a leading peer-reviewed journal published by SPRINGER INT PUBL AG that focuses on the dynamic and rapidly evolving fields of pharmaceutical sciences, including drug discovery, pharmacology, and toxicology. With an impressive Q2 ranking in both Drug Discovery and Miscellaneous Medicine categories for 2023, this journal stands out as a vital resource for researchers, professionals, and students alike, offering a platform for significant contributions to the scientific community. Covering a comprehensive scope from 2000 to 2024 and indexed by Scopus, the journal ranks within the top percentile in its field, with a ranking of #66/313 in Pharmacology and #34/157 in Drug Discovery, reaffirming its impact and relevance. The journal promotes open access to foster widespread dissemination of knowledge in pharmaceutical sciences, ultimately aiming to bridge the gap between research and clinical applications. For those looking to stay at the forefront of pharmaceutical innovation, DARU represents an invaluable connection to the latest studies and breakthrough findings.

Pakistan Journal of Pharmaceutical Sciences

Delivering critical studies that shape the pharmaceutical landscape.
Publisher: UNIV KARACHIISSN: 1011-601XFrequency: 4 issues/year

Pakistan Journal of Pharmaceutical Sciences, published by the University of Karachi, serves as a vital platform for advancing research in the field of pharmaceutical sciences. With a strong commitment to disseminating innovative findings and critical studies since its inception in 1995, the journal focuses on a wide array of topics including pharmacology, toxicology, and pharmaceutics. With an ISSN of 1011-601X, it holds a reputable position within the academic community, reflecting its Q3 category ranking in Pharmaceutical Science as of 2023. While the journal is currently not designated as Open Access, it remains accessible through institutional subscriptions, ensuring that both emerging and established researchers can contribute to and benefit from its scholarly content. This publication not only promotes scientific dialogue but also aims to bridge the gap between academia and industry, appealing to a diverse audience of researchers, professionals, and students seeking to stay informed about the latest advancements and trends in pharmaceutical research.

CURRENT DRUG TARGETS

Elevating Drug Discovery to New Heights
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1389-4501Frequency: 16 issues/year

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

MOLECULAR PHARMACOLOGY

Transforming Pharmacology through Rigorous Research
Publisher: AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICSISSN: 0026-895XFrequency: 12 issues/year

MOLECULAR PHARMACOLOGY, published by the American Society for Pharmacology and Experimental Therapeutics, is an influential peer-reviewed journal dedicated to advancing the field of pharmacology through comprehensive research on molecular mechanisms of drug action. With an impressive historic convergence from 1965 to 2024, this journal plays a pivotal role in disseminating high-quality research, showcasing significant findings that impact both clinical and experimental pharmacology. Notably, it holds a distinguished Q1 ranking in Pharmacology and a Q2 ranking in Molecular Medicine as of 2023, reflecting its prominence in the academic community. Researchers and practitioners engaged in pharmacological studies will benefit from the journal’s focus on new therapeutic strategies, drug development, and the molecular basis of drug action. While MOLECULAR PHARMACOLOGY is not an open-access journal, it offers a wealth of knowledge behind a subscription model, ensuring that contributors and readers maintain a high standard of academic rigor. Address all inquiries to the editorial office located at 9650 Rockville Pike, Bethesda, MD 20814-3995, United States.

Pharmaceutical Sciences

Pioneering research at the intersection of science and health.
Publisher: TABRIZ UNIV MEDICAL SCIENCES, FAC PHARMACYISSN: 1735-403XFrequency: 4 issues/year

Pharmaceutical Sciences, an esteemed journal published by Tabriz University of Medical Sciences, Faculty of Pharmacy, serves as a crucial platform for the dissemination of pioneering research in the fields of pharmaceutical science, pharmacology, and toxicology. With an impact factor reflective of its substantial contribution to the scientific community, this open access journal has been accessible since 2012, ensuring that researchers, professionals, and students worldwide can engage with its rich content. Located in Iran, it has continually evolved, covering research from 2009 to 2024, and boasts impressive rankings in multiple Scopus categories, including Q3 in Pharmaceutical Science and Q2 in Pharmacology, Toxicology and Pharmaceutics. By bridging gaps between scientific inquiry and practical applications, Pharmaceutical Sciences is dedicated to advancing pharmaceutical knowledge and promoting innovative practices that address significant health challenges.

BIOCHEMICAL PHARMACOLOGY

Uniting science and medicine for impactful pharmaceutical advancements.
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0006-2952Frequency: 12 issues/year

BIOCHEMICAL PHARMACOLOGY, published by PERGAMON-ELSEVIER SCIENCE LTD, stands as a leading international journal devoted to the advancing field of biochemical pharmacology. Since its inception in 1958, the journal has continuously offered a platform for innovative research, delivering critical insights into the interaction between biochemical processes and pharmaceutical applications, and now converges towards its 2024 edition. With an impressive Q1 ranking in both Biochemistry and Pharmacology categories, it ranks 32nd out of 313 in Pharmacology and Toxicology, and 58th out of 438 in Biochemistry according to Scopus, showcasing its significant impact within the scientific community. Researchers and professionals rely on this journal to keep abreast of essential developments, given its robust peer-review process and a comprehensive selection of articles that span experimental studies, clinical trials, and theoretical analyses. Although not an Open Access journal, it remains pivotal for those seeking to advance their knowledge in the dynamic fields of biochemistry and pharmacology. With its high impact factor and emphasis on quality research, BIOCHEMICAL PHARMACOLOGY continues to be an invaluable resource for students, researchers, and industry professionals striving to make breakthroughs in drug development and therapeutic strategies.

Frontiers in Pharmacology

Empowering researchers with cutting-edge insights in pharmacology.
Publisher: FRONTIERS MEDIA SAISSN: Frequency: 1 issue/year

Frontiers in Pharmacology, published by FRONTIERS MEDIA SA, stands as a leading open-access journal dedicated to advancing the field of pharmacology since its inception in 2010. With its ISSN 1663-9812, the journal is based in Switzerland and maintains a vital role in disseminating innovative research findings that span various disciplines within pharmacology, including pharmacokinetics, toxicology, and pharmacogenetics. In 2023, Frontiers in Pharmacology has achieved an impressive standing within the scientific community, being ranked in the Q1 category for both general and medical pharmacology, highlighting its critical contribution to the field with a Scopus ranking of #41 out of 272 in medical pharmacology and #76 out of 313 in pharmacology, toxicology, and pharmaceutics, placing it in the 75th and 85th percentiles, respectively. Researchers and practitioners benefit from its open-access model, which ensures widespread accessibility to groundbreaking research, fostering collaboration and innovation across the pharmaceutical sciences. With its commitment to excellence, Frontiers in Pharmacology serves as an essential resource for those looking to explore and contribute to the latest advancements in pharmacological research.

ANTI-CANCER DRUGS

Advancing the Frontiers of Cancer Therapeutics
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0959-4973Frequency: 10 issues/year

ANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Exploring Innovations in Drug Action and Safety
Publisher: WILEYISSN: 1742-7835Frequency: 12 issues/year

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.